MedTrace Logo

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

NCT04272658 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2024-06-26

No results posted yet for this study

Summary

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..

Conditions

Interventions

DIAGNOSTIC_TEST

value of 4D body-to-whole dynamic acquisition in FDG

differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this "unconfirmed progression" after 2 new treatment cures of ICI

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Ronan ABGRAL, MD-PhD · Nuclear Medecine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-26
Primary Completion
2026-06-26
Completion
2026-06-26
FDA Device
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04272658 on ClinicalTrials.gov